Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia Research Letter

  

Authors:	Przespolewski, A.; Goldberg, A. D.; Talati, C.; Fazal, S.; Vachhani, P.; Sanikommu, S. R.; Thota, S.; Waksal, J.; Ball, B.; Famulare, C.; Stahl, M.; Baron, J.; Griffiths, E. A.; Thompson, J. E.; Sweet, K.; Wang, E. S.
Title:	Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia
Keywords:	adult; controlled study; event free survival; treatment response; middle aged; human cell; major clinical study; leukemia, myeloid, acute; drug efficacy; drug safety; drug approval; cancer patient; cytarabine; follow up; antineoplastic agent; multiple cycle treatment; bleeding; antineoplastic combined chemotherapy protocols; cytogenetics; hematopoietic stem cell transplantation; food and drug administration; medical record review; retrospective study; cancer mortality; febrile neutropenia; daunorubicin; neoplasms, second primary; second cancer; eligibility; acute myeloid leukemia; humans; human; male; female; article; cytarabine plus daunorubicin; secondary acute myeloid leukemia; cpx-351
Journal Title:	Blood
Volume:	141
Issue:	12
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2023-03-23
Start Page:	1489
End Page:	1493
Language:	English
DOI:	10.1182/blood.2022016678
PUBMED:	36493344
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148855505&doi=10.1182%2fblood.2022016678&partnerID=40&md5=d81d46ee2b3b7289e0419b7b43f5268a
Notes:	Article -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/204293